SAN DIEGO, Calif. and CAMBRIDGE, Mass., April 13, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that preclinical studies evaluating IPI-926, Infinity's novel Hedgehog pathway inhibitor, demonstrated that the compound has excellent pharmaceutical properties in vivo, including oral bioavailability, potent inhibition of the Hedgehog pathway, and long plasma and tumor half-life. Notably, in a novel mouse model of medulloblastoma, once-daily dose administration of IPI-926 resulted in 100 percent survival during the treatment period. These data were reported in an oral presentation today by Melissa Pink, a research investigator at Infinity, during the Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California.
